StemCell Therapy

BALTIMORE, Oct. 31, 2019 /PRNewswire/ --Deadly. Blinding. Costly. Epidemic. These are the words used to describe diabetes, a devastating condition affecting more than 30 million Americans (about 9.4% of the population). Of those, nearly 30 percent (or 10 million people), have diabetic retinopathy, a potentially blinding disease that costs Americans more than $500 million every year.

The new Versant Health white paper, The health and financial costs of diabetic retinopathy, outlines the toll both physically and financially that diabetic retinopathy can take on a person. Not only can the disease have a debilitating impact on vision, but medical costs associated with diabetic retinopathy are higher than with other diabetes-related conditions, including neuropathy and chronic kidney disease.

"Early intervention is critical when it comes to the successful treatment of diabetic retinopathy," says Mark Ruchman, MD, Chief Medical Officer at Versant Health and contributor to the white paper "In its early stages, when treatment has the greatest likelihood of success, patients are typically asymptomatic. Thus, a regular eye exam is a critical component of any health and wellness program to reduce blindness from this disease."

Versant Health supports the overall health of its diabetic members in several ways, striving to reduce the risk for and/or severity of diabetic eye disease, including Diabetic Outreach, medical management, and detailed provider portal questionnaires. To learn more, download the health and financial costs of diabetic retinopathy white paperfrom the Versant Health website.

About Versant HealthVersant Health is one of the nation's leading managed vision care companies serving more than 33 million members nationwide. Through our Davis Vision plans and Superior Vision plans, we help members enjoy the wonders of sight through healthy eyes and vision. Providing vision and eye health solutions that range from routine vision benefits to medical management, Versant Health has a unique visibility and scale across the total eye health value chain.As a result, members enjoy a seamless experience with access to one of the broadest provider networks in the industry and an exclusive frame collection.Commercial groups, individuals, third parties, and health plans that serve government-sponsored programs such as Medicaid and Medicare are among our valued customers.

For more information visitversanthealth.com.

SOURCE Versant Health

versanthealth.com

Originally posted here:
Versant Health releases white paper: The health and financial costs of diabetic retinopathy - PRNewswire

This entry was posted on November 1, 2019 at 8:46 am and is filed under Diabetes. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |